Cited 2 times in
Frequency of peripheral diseases in Korean patients with ankylosing spondylitis and the effectiveness of adalimumab
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 박민찬 | - |
dc.date.accessioned | 2022-09-02T01:08:54Z | - |
dc.date.available | 2022-09-02T01:08:54Z | - |
dc.date.issued | 2020-09 | - |
dc.identifier.issn | 1756-1841 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/190005 | - |
dc.description.abstract | Aim Peripheral features contribute to disease burden in ankylosing spondylitis (AS). This study investigated the frequency of peripheral disease and effectiveness of adalimumab among Korean patients with AS. Methods Peripheral disease was evaluated in consecutively enrolled patients with active AS (Bath Ankylosing Spondylitis Disease Activity Index [BASDAI] score >= 4). An adult subpopulation was subsequently enrolled in a prospective, observational study and received adalimumab 40 mg, every 2 weeks. During a 52-week follow-up, AS disease activity was assessed by BASDAI score, and effectiveness in peripheral disease assessed via changes in Maastricht Ankylosing Spondylitis Enthesitis Score (MASES; 0-13), swollen joint and tender joint counts (SJC, 0-44; TJC, 0-46), and dactylitic digits from baseline. Results Of 1161 Korean patients with AS, 178 (15.3%) and 306 (26.4%) had enthesitis and peripheral arthritis, respectively; dactylitis was diagnosed in 28 patients (2.4%). Of 201 patients enrolled in the observational study, 46.3%, 33.3%, and 3.0% had enthesitis, peripheral arthritis, and dactylitis, respectively. Overall, 75.1% of patients achieved >50% improvement in BASDAI score by week 12. Mean MASES was significantly reduced from 2.67 at baseline to 0.85 and 0.34 at weeks 12 and 52, respectively (P < .0001). Similarly, SJC and TJC improved significantly from 2.58 and 3.49 at baseline to 0.80 and 1.68, respectively, by week 12 (P < .0001). Dactylitis was resolved in all affected patients by week 28. Conclusion Of these Korean patients with AS, those who received adalimumab demonstrated higher prevalence for peripheral symptoms and, subsequently, adalimumab treatment improved peripheral features of their AS. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Wiley on behalf of the Asia Pacific League of Associations for Rheumatology | - |
dc.relation.isPartOf | INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Adalimumab / adverse effects | - |
dc.subject.MESH | Adalimumab / therapeutic use* | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Antirheumatic Agents / adverse effects | - |
dc.subject.MESH | Antirheumatic Agents / therapeutic use* | - |
dc.subject.MESH | Arthritis / diagnosis | - |
dc.subject.MESH | Arthritis / drug therapy* | - |
dc.subject.MESH | Arthritis / epidemiology | - |
dc.subject.MESH | Enthesopathy / diagnosis | - |
dc.subject.MESH | Enthesopathy / drug therapy* | - |
dc.subject.MESH | Enthesopathy / epidemiology | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Prevalence | - |
dc.subject.MESH | Prospective Studies | - |
dc.subject.MESH | Republic of Korea / epidemiology | - |
dc.subject.MESH | Spondylitis, Ankylosing / diagnosis | - |
dc.subject.MESH | Spondylitis, Ankylosing / drug therapy* | - |
dc.subject.MESH | Spondylitis, Ankylosing / epidemiology | - |
dc.subject.MESH | Time Factors | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | Frequency of peripheral diseases in Korean patients with ankylosing spondylitis and the effectiveness of adalimumab | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Sang-Hoon Lee 1 | - |
dc.contributor.googleauthor | Won Park 2 | - |
dc.contributor.googleauthor | Sung Won Lee 3 | - |
dc.contributor.googleauthor | Hyun Ah Kim 4 | - |
dc.contributor.googleauthor | Jung-Yoon Choe 5 | - |
dc.contributor.googleauthor | Sang-Heon Lee 6 | - |
dc.contributor.googleauthor | Shin-Seok Lee 7 | - |
dc.contributor.googleauthor | Sung-Hwan Park 8 | - |
dc.contributor.googleauthor | Min-Chan Park 9 | - |
dc.contributor.googleauthor | Dong-Hyuk Sheen 10 | - |
dc.contributor.googleauthor | Hye Soon Lee 11 | - |
dc.contributor.googleauthor | Yeon-Ah Lee 12 | - |
dc.contributor.googleauthor | Yusun Lee 13 | - |
dc.contributor.googleauthor | Tae-Hwan Kim 14 | - |
dc.identifier.doi | 10.1111/1756-185X.13917 | - |
dc.contributor.localId | A01470 | - |
dc.relation.journalcode | J01158 | - |
dc.identifier.eissn | 1756-185X | - |
dc.identifier.pmid | 32725789 | - |
dc.subject.keyword | adalimumab | - |
dc.subject.keyword | ankylosing spondylitis | - |
dc.subject.keyword | dactylitis | - |
dc.subject.keyword | enthesitis | - |
dc.subject.keyword | Korea | - |
dc.subject.keyword | peripheral arthritis | - |
dc.subject.keyword | peripheral disease | - |
dc.contributor.alternativeName | Park, Min Chan | - |
dc.contributor.affiliatedAuthor | 박민찬 | - |
dc.citation.volume | 23 | - |
dc.citation.number | 9 | - |
dc.citation.startPage | 1175 | - |
dc.citation.endPage | 1183 | - |
dc.identifier.bibliographicCitation | INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, Vol.23(9) : 1175-1183, 2020-09 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.